Delving into the Latest Updates on JRF-104 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

AXL inhibitors(AXL receptor tyrosine kinase inhibitors), CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersHemic and Lymphatic Diseases

Active Indication

Advanced Malignant Solid NeoplasmEsophageal CarcinomaAcute Myeloid Leukemia

Inactive Indication-

Originator Organization

Chengdu Jinruijiye Biotechnology Co., Ltd

Active Organization

Chengdu Jinruijiye Biotechnology Co., Ltd

Shanghai Xunhe Pharmaceutical Technology Co., Ltd

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This study is an exploratory clinical trial and does not involve statistical assumptions or sample size estimation. the mainly purpose for the study is to evaluate the safety of XH-30002 capsule combined with afatinib tablets in the treatment of locally advanced or metastatic esophageal squamous cell carcinoma.

Start Date01 Jun 2023

Sponsor / Collaborator

Fujian Cancer Hospital

CTR20202519

/ RecruitingPhase 1

一项评价XH-30002胶囊口服给药在晚期实体瘤患者中的安全性、耐受性、药代动力学特征和初步疗效的Ⅰ期临床研究

[Translation] A Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of oral XH-30002 capsules in patients with advanced solid tumors

观察XH-30002胶囊在晚期实体瘤患者中的安全性和耐受性，确定XH-30002胶囊单次及多次口服给药在晚期实体瘤患者中的最大耐受剂量（MTD）和/或II期推荐剂量（RP2D）。

[Translation]

To observe the safety and tolerability of XH-30002 capsules in patients with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D) of XH-30002 capsules after single and multiple oral administration in patients with advanced solid tumors.

Start Date16 Aug 2021

Sponsor / Collaborator

Shanghai Xunhe Pharmaceutical Technology Co., Ltd

ChiCTR2100043865

/ RecruitingPhase 1IIT

A phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of XH-30002 capsules administered orally in patients with advanced solid tumors

Start Date01 Mar 2021

Sponsor / Collaborator-

100 Clinical Results associated with JRF-104

Login to view more data

100 Translational Medicine associated with JRF-104

Login to view more data

100 Patents (Medical) associated with JRF-104

Login to view more data

100 Deals associated with JRF-104

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	CN	Shanghai Xunhe Pharmaceutical Technology Co., Ltd	16 Aug 2021
Esophageal Carcinoma	Preclinical	CN	Chengdu Jinruijiye Biotechnology Co., Ltd	15 Aug 2024
Acute Myeloid Leukemia	Preclinical	CN	Chengdu Jinruijiye Biotechnology Co., Ltd	15 Aug 2020